Abstract

A PROSPECTIVE OBSERVATIONAL STUDY ON THE EFFECTIVENESS OF SUPRA BIOAVILABLE ITRACONAZOLE (SUBA) WITH CONVENTIONAL ITRACONAZOLE IN DERMATOPHYTOSIS

*Dr. Sk. Mulla Mobin, Pharm. D., Dr. K. Sruthi, M.D., D.V.L., Dr. J.N. Suresh Kumar, Ch. Preeti Sri, G. Prathyusha, K. Ram Bhupal Naik and R. Jayanthi

ABSTRACT

Dermatophytosis is the commonest alarming fungal infection with a prevalence of 36.60% - 78.40% in India. Dermatophytosis is caused by the dermatophytes such as trichophyton, microsporum and epidermophyton. Dermatophytes have the ability to colonize and metabolize the keratinized tissues like skin, hair and nails; usually dermatophytosis is clinically presented as tinea pedis, tinea Corporis, tinea cruris etc Due to more humid and warmer climate, the absurd use of topical corticosteroid-based combinations increases the risk of developing dermatophytosis. Itraconazole is a broad spectrum systemic triazole antifungal agent used in the management of dermatophytosis in India. A newer Itraconazole formulation that is, super bioavailable itraconazole is claimed to overcome all the pharmacokinetic challenges faced with conventional Itraconazole. Super bioavailable Itraconazole have been claimed to have the benefits of increased bioavailability, no food interactions, less inter subject variability, no reduction in absorption with concomitant use of PPI not seen with other gastric acid lowering agents which are seen with conventional Itraconazole. All these benefits can be anticipated to improve the clinical outcomes as well as the patient compliance. Objective: The main objective of the study is to assess the effectiveness of supra bioavailable Itraconazole with conventional Itraconazole in dermatophytosis. Methodology: It is a prospective observational study conducted to compare the effectiveness of supra bioavailable Itraconazole with conventional Itraconazole by using data collection forms. A personal visit was made to all the patients who were included in the study to collect any further information. Their medications were cross- checked with the treatment chart. All the patients were monitored at the time of visit, follow up-1, and follow up-2. Results: In this study a total of 160 cases, demographic date reveals that 71 patients (44.37%) were males and 89 patients (55.62%) were females. Female patients are more in number when compared to males. The age group distribution of patients reveals that majority of the people belong to the age group 11-20yrs with a total of 52 patients (32.50%). The age group 41-50 yrs has least number of patients (14 patients, 18.12%). While checking the prescription for the type of drug prescribed most of the prescriptions were found to have conventional Itraconazole (103 patients, 64.37%) followed by SUBA Itraconazole (57 patients, 35.62%). In the diagnosis most of the patients were found to have Tinea Corporis (69 patients, 43.12%). While checking for their occupation most of them were students (n=57, 35.62%).160 patients have active patch status at the time of visit. At follow up 1, 8 patients (8.60%) have active patch status and 67 patients (72.04%) have ghosting appearance and 18 patients (19.35%) have patch status of healed with or without hyper pigmentation. At follow up 2 out of 40 patients 23 patients (57.50%) have (12.50%) have active patch status and 2 patients (5%) have ghosting appearance. Conclusion: The present study concludes the effectiveness of supra bioavailable Itraconazole when compared with conventional Itraconazole. In our study population of 160 patient’s female were more in number when compared to males. Majority of prescriptions were found to have conventional Itraconazole in treating dermatophytosis. The newer formulation of Itraconazole i.e., SUBA Itraconazole has greater effectiveness when compared to Itraconazole. The use of conventional Itraconazole was high than SUBA Itraconazole. Physician should be made to know the effectiveness of SUBA and its role in the dermatophytosis as the patients who were kept on SUBA Itraconazole achieved better clinical clearance.

Keywords: Dermatophytosis, Suba itraconozole, Conventional itraconozole.